Abstract: A technology of starting power supply from an external device to a load device in a shorter period, after detection of connection between the external device and the load device, is provided. A control device includes a first connector attachable to and detachable from an external device, a power supply path to electrically connect a load device and the first connector, a load switch to switch between connection and disconnection of the power supply path, a protection circuit to protect the load switch from an inrush current to the load switch, the protection circuit including at least a capacitor, and a control circuit. The control circuit is operable to switch the load switch from disconnection to connection after a total time of a preset set time and a first time based on a charging time of the capacitor which has elapsed since connection of the first connector to the external device was detected.

Abstract: The present invention relates to an oral solid dosage form comprising N2-{[1-ethyl-6-(4-methylphenoxy)-1H-benzimidazol-2-yl]methyl}-L-alaninamide, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof as an active ingredient, which has good dissolution and storage-stability. When the oral solid dosage form is a tablet, the tablet can be prepared while inhibiting tableting troubles from low content to high content of the active ingredient.

Abstract: The present disclosure provides a compound that exerts an anticancer action based on CHK1 inhibition. The present disclosure was completed by finding that a compound represented by formula (1) or a pharmaceutically acceptable salt thereof exhibits an excellent antitumor action by having a potent inhibitory action against CHK1: wherein R1, R2, L, V, W, and Q are as defined herein, X, Y, and Z each independently represent CR8 or a nitrogen atom, wherein X, Y, and Z are not simultaneously CR8, and R8 is as defined herein.

Abstract: The present disclosure provides a compound that exerts an anticancer action based on CHK1 inhibition. The present disclosure was completed by finding that a compound represented by formula (1) or a pharmaceutically acceptable salt thereof exhibits an excellent antitumor action by having a potent inhibitory action against CHK1: wherein R1, R2, L, V, W, and Q are as defined herein, X, Y, and Z each independently represent CR8 or a nitrogen atom, wherein X, Y, and Z are not simultaneously CR8, and R8 is as defined herein.

Abstract: A device according to one embodiment includes a first battery to output alternating-current power for driving a motor and connected to a first main circuit that is connected to an inverter; a second battery connected to a second main circuit, having a storage capacity larger than it of the first battery, and having a permissible power output per unit storage capacity smaller than it of the first battery; a DC/DC converter to convert a voltage of the second main circuit to a predetermined voltage and output to the first main circuit; a control circuit to control charging and discharging operations of the first and the second battery and an operation of the DC/DC converter; a first terminal connected to a positive terminal of the first battery; and a second terminal connected to a negative terminal of the first battery.

Abstract: The present disclosure provides a compound that exerts an anticancer action based on CHK1 inhibition. The present disclosure was completed by finding that a compound represented by formula (1) or a pharmaceutically acceptable salt thereof exhibits an excellent antitumor action by having a potent inhibitory action against CHK1: wherein R1, R2, L, V, W, and Q are as defined herein, X, Y, and Z each independently represent CR8 or a nitrogen atom, wherein X, Y, and Z are not simultaneously CR8, and R8 is as defined herein.

Abstract: A battery control device of embodiments includes at least two transistors and a control unit. The at least two transistors are at least two transistors that are connected to a battery in series and control charging of the battery, include body diodes, respectively, and are connected in series such that respective body diodes are arranged in the same direction. The control unit changes a conduction pattern in which a conduction state and a non-conduction state of the at least two transistors are switched, and determines whether at least one of the at least two transistors has an abnormality on the basis of a change in a measured voltage.

Abstract: An oral disintegrating tablet containing (1) D-mannitol, (2) an active ingredient, (3) one or more disintegrating agents selected from the group consisting of crospovidone and carmellose, and (4) one or more lubricants selected from the group consisting of sodium stearyl fumarate and sucrose esters of fatty acids. The oral disintegrating tablet of the present invention has some excellent properties of (1) allowing easy production in a common facility without necessitating a specialized pharmaceutical technique, (2) having an appropriate strength that does not breakdown in the process of distribution, (3) having a fast disintegrating ability in the oral cavity, and (4) also having excellent ingestion feel such as greatly reduced bitterness or gritty feel; therefore, the tablet can be suitably used as a dosage form that is suitable for aged individuals, children, and seriously ill patients.

Abstract: A battery assembly system includes: a battery assembly; a temperature measuring part; and a monitoring device. The battery assembly includes a plurality of batteries connected in series. The temperature measuring part measures temperatures of connection parts used to connect electrodes of batteries included in the battery assembly. The monitoring device derives temperatures of the batteries on the basis of the temperatures measured by the temperature measuring part.

Abstract: According to an embodiment, a degradation estimation method includes detecting a stop interval of a battery control apparatus having a function to calculate a state of charge of a battery, acquiring degradation information corresponding to a calculated state of charge calculated from the battery and a detection temperature detected from the battery or degradation information corresponding to the calculated state of charge and an ambient temperature based on a first degradation information database showing degradation of the battery in accordance with a set state of charge and a set temperature, and estimating the degradation of the battery in the stop interval based on the degradation information acquired.

Abstract: An optical line terminal includes the transmission rate control table for storing a minimum bandwidth for an emergency status for each of optical network units in addition to a maximum assigned bandwidth in a normal status. When a decrease in a supply power is detected, the optical line terminal calculates a transmission clock rate providing a minimum bandwidth required by each optical network unit with reference to the transmission rate control table. The optical line terminal determines change timing of downstream and upstream transmission clock rates, and change timing of upstream data for time-division multiplexing to instruct each of the optical network units. Both the optical line terminal and the optical network unit change the transmission clock rates with substantial synchronization therebetween.

Abstract: An oral disintegrating tablet containing (1) D-mannitol, (2) an active ingredient, (3) one or more disintegrating agents selected from the group consisting of crospovidone and carmellose, and (4) one or more lubricants selected from the group consisting of sodium stearyl fumarate and sucrose esters of fatty acids. The oral disintegrating tablet of the present invention has some excellent properties of (1) allowing easy production in a common facility without necessitating a specialized pharmaceutical technique, (2) having an appropriate strength that does not breakdown in the process of distribution, (3) having a fast disintegrating ability in the oral cavity, and (4) also having excellent ingestion feel such as greatly reduced bitterness or gritty feel; therefore, the tablet can be suitably used as a dosage form that is suitable for aged individuals, children, and seriously ill patients.

Abstract: An oral disintegrating tablet containing (1) D-mannitol, (2) an active ingredient, (3) one or more disintegrating agents selected from the group consisting of crospovidone and carmellose, and (4) one or more lubricants selected from the group consisting of sodium stearyl fumarate and sucrose esters of fatty acids. The oral disintegrating tablet of the present invention has some excellent properties of (1) allowing easy production in a common facility without necessitating a specialized pharmaceutical technique, (2) having an appropriate strength that does not breakdown in the process of distribution, (3) having a fast disintegrating ability in the oral cavity, and (4) also having excellent ingestion feel such as greatly reduced bitterness or gritty feel; therefore, the tablet can be suitably used as a dosage form that is suitable for aged individuals, children, and seriously ill patients.

Abstract: A communication apparatus according to the present invention includes a presence information setting unit that sets presence information including a user display name and its apparatus state, and a presence information notification unit that that notifies an opposing apparatus of the presence information. The communication apparatus further include an action information acquisition unit that detects an opposing user action of the opposing apparatus. The communication apparatus determines that the user is “Away” or “Not Available” when the action information detector detects no user reaction after a predetermined time has passed since the opposing apparatus user's action was detected.

Abstract: An objective of the present invention is to provide gibberellin-binding proteins, genes encoding such proteins, and applications therefor. The proteins of the present invention function as cytoplasmic receptors for gibberellin and mediate gibberellin response in plants. Plants overexpressing such genes exhibited gibberellin-hypersensitive phenotypes, such as increased plant height. In contrast, plants in which the genes were mutated exhibited gibberellin-insensitive phenotypes, and thus became dwarfed. Accordingly, plant differentiation and growth can be regulated by introducing the gibberellin-binding genes of the present invention or by suppressing the expression of same.

Abstract: A gene relating to the regeneration ability of plants was successfully isolated and identified using linkage analysis. Furthermore, methods for breeding highly regenerative varieties, methods for transforming unculturable varieties, and methods for selecting transformed cells, wherein these methods utilize this gene, were also discovered. The present invention is useful in fields such as cultivar improvement and gene analysis that uses transformation methods.

Abstract: An oral disintegrating tablet containing (1) D-mannitol, (2) an active ingredient, (3) one or more disintegrating agents selected from the group consisting of crospovidone and carmellose, and (4) one or more lubricants selected from the group consisting of sodium stearyl fumarate and sucrose esters of fatty acids. The oral disintegrating tablet of the present invention has some excellent properties of (1) allowing easy production in a common facility without necessitating a specialized pharmaceutical technique, (2) having an appropriate strength that does not breakdown in the process of distribution, (3) having a fast disintegrating ability in the oral cavity, and (4) also having excellent ingestion feel such as greatly reduced bitterness or gritty feel; therefore, the tablet can be suitably used as a dosage form that is suitable for aged individuals, children, and seriously ill patients.

Abstract: 3-[(1S)-1-(2-fluorobiphenyl-4-yl)ethyl]-5-[[amino(morpholin-4-yl)methylene]amino]isoxazole is an isoxazole compound useful as a therapeutic agent for an autoimmune disease. The isoxazole compound can be stabilized by using an antioxidant such as a metabisulfite, bisulfite, sulfite or dibutylhydroxytoluene. A pharmaceutical composition for oral administration comprising the isoxazole compound and the antioxidant is an excellent pharmaceutical composition, since the isoxazole compound contained in the composition is stabilized.

Abstract: An objective of the present invention is to provide gibberellin-binding proteins, genes encoding such proteins, and applications therefor. The proteins of the present invention function as cytoplasmic receptors for gibberellin and mediate gibberellin response in plants. Plants overexpressing such genes exhibited gibberellin-hypersensitive phenotypes, such as increased plant height. In contrast, plants in which the genes were mutated exhibited gibberellin-insensitive phenotypes, and thus became dwarfed. Accordingly, plant differentiation and growth can be regulated by introducing the gibberellin-binding genes of the present invention or by suppressing the expression of same.

Abstract: A gene that regulates the increase and decrease of the particle-bearing number (including glumous flowers, fruits, and seeds) of plants was successfully isolated and identified by a linkage analysis. In addition, breeding methods that utilize this gene to increase the particle-bearing number (including glumous flowers, fruits, and seeds) of plants were also discovered. The present invention is useful in fields such as breeding of improved plant varieties.